{{Rsnum
|rsid=1143672
|Gene=SLC15A2
|Chromosome=3
|position=121929321
|Orientation=plus
|GMAF=0.4908
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=SLC15A2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 18.5 | 56.9 | 24.6
| HCB | 57.8 | 37.8 | 4.4
| JPT | 55.8 | 41.9 | 2.3
| YRI | 28.6 | 47.6 | 23.8
| ASW | 0.0 | 0.0 | 0.0
| CHB | 57.8 | 37.8 | 4.4
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1143672
|Name_s=SLC15A2: K509R
|Gene_s=SLC15A2
|Feature=Exon/NonSyn
|Evidence=PubMed ID:19940846
|Annotation=PEPT2*1 (350L-409P-509R) showed lower K m for glycyl-sarcosine as compared with PEPT2*2 (350F- 409S-509K) in transfected cells.
|Drugs=glycyl-sarcosine
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA165111600
}}

{{GET Evidence
|gene=SLC15A2
|aa_change=Arg509Lys
|aa_change_short=R509K
|impact=not reviewed
|qualified_impact=Insufficiently evaluated not reviewed
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1143672
|overall_frequency_n=5047
|overall_frequency_d=10758
|overall_frequency=0.469139
|n_genomes=41
|n_genomes_annotated=0
|n_haplomes=51
|n_articles=0
|n_articles_annotated=0
|nblosum100=-3
|autoscore=0
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}